|
Baseline patient characteristics according to Glycoprotein IIIa (GP IIIa) polymorphism |
||||
| GP IIIa A1/A2 genotype |
||||
|
|
||||
| A1/A1 (n = 690) |
A1/A2 (n = 248) |
A2/A2 (n = 25) |
p |
|
|
|
||||
| Demographic characteristics |
||||
| Male sex (%) |
80.9 |
82.7 |
64 |
0.077 |
| Age (mean ± SD, years) |
64.4 ± 11.2 |
64.4 ± 11.4 |
66.2 ± 10.3 |
0.717 |
| Age ≥ 65 years (%) |
53.9 |
51.6 |
64 |
0.470 |
| Medical history |
||||
| Hypertension (%) |
42.0 |
43.1 |
32 |
0.560 |
| Diabetes mellitus (%) |
12.3 |
14.1 |
12 |
0.763 |
| Hypercholesterolemia (%) |
51.6 |
50.4 |
56 |
0.512 |
| Past or current smokers (%) |
50.6 |
53.2 |
40 |
0.417 |
| Body Mass Index>25 (kg/m2) (%) |
63.5 |
66.1 |
52 |
0.293 |
| Family history of CAD (%) |
27.8 |
29.8 |
24 |
0.755 |
| Prior MI (%) |
31.2 |
30.2 |
28 |
0.915 |
| Prior PCI (%) |
13.0 |
15.3 |
0 |
0.065 |
| Prior CABG (%) |
10 |
8.1 |
0 |
0.204 |
| Indication for PCI |
||||
| Stable angina (%) |
14.3 |
18.1 |
16 |
0.752 |
| Unstable angina (%) |
38.3 |
35.9 |
28 |
|
| Acute MI (%) |
29.3 |
27.0 |
32 |
|
| Post MI (%) |
11.4 |
12.1 |
16 |
|
| Other (%) |
4.5 |
5.2 |
8 |
|
| Angiographic characteristics |
||||
| LVEF < 40% (%) |
15.7 |
16.1 |
8 |
0.716 |
| Single vessel disease (%) |
45.4 |
42.7 |
32 |
0.576 |
| Two-vessel disease (%) |
32.2 |
35.5 |
36 |
|
| Three-vessel disease (%) |
22.5 |
21.8 |
32 |
|
| Therapy at inclusion |
||||
| ACE inhibitor (%) |
32.3 |
33.1 |
44 |
0.481 |
| Beta-blocker (%) |
56.1 |
56.0 |
80 |
0.060 |
| Statin (%) |
35.2 |
33.5 |
32 |
0.864 |
|
ACE, angiotensin converting enzyme; CABG, coronary artery bypass graft; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention. | ||||
Le Hello et al. Thrombosis Journal 2007 5:19 doi:10.1186/1477-9560-5-19 |
||||